Bio-Rad reported third-quarter 2026 net sales of $656.4 million, up 0.5% from a year earlier, and GAAP net income of $458.6 million, compared with a loss of $341.9 million in the prior-year quarter. The GAAP net income reflects a $588.2 million gain from the change in fair market value of its equity securities, while GAAP operating results were a loss of $49.7 million, including restructuring and impairment charges. The company kept its full-year 2026 outlook unchanged.
Net sales were $656.4 million, up 0.5%; currency-neutral sales rose 0.7%, led by Clinical Diagnostics.
GAAP net income was $458.6 million, or $17.02 per diluted share, versus a loss of $341.9 million, or $12.70 per share, a year earlier.
GAAP operating loss was $49.7 million, including $77.2 million of restructuring charges and a $49.8 million impairment of purchased intangibles.
Non-GAAP diluted income per share was $2.65, up from $2.26; full-year outlook was reaffirmed.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Bio-Rad Laboratories's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$2.58B
+0.7%
$27.85
—
29.4%
FY2024
$2.57B
-3.9%
$-65.36
—
-71.9%
FY2023
$2.67B
-4.7%
$-21.82
—
-23.9%
FY2022
$2.80B
-4.1%
$-121.79
-186.5%
-129.5%
FY2021
$2.92B
+14.8%
$140.83
+11.4%
145.6%
Frequently asked questions
When is Bio-Rad Laboratories's next earnings date?
Bio-Rad Laboratories has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Bio-Rad Laboratories earn last quarter?
For the quarter ended Sep 2026, Bio-Rad Laboratories reported diluted EPS of $17.02 on revenue of $656.40M (+0.5%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.